Strong Novo performance leads to C20 index record

C20 ends Tuesday at a record high, but it’s not a sign that the economic crisis is over

The largest stocks on the C20 index closed Tuesday at 517.98, setting an all-time record.

Tuesday’s performance bested the previous record set in October 2007, which was before the global economic crisis took hold.

But Michael Kongshaug, the chief analyst for Danske Bank, warned against taking Tuesday’s C20 performance as a sign that the crisis is winding down. He said that it was an indicator of just one business’s success.

“Novo Nordisk is so big that it alone has a weight of over 40 percent of the index,” Kongshaug told Ritzau. “The company is doing fantastic and is pulling the rest of the stocks up with it.”

But it's not just Novo. Kongshaug also pointed to strong performances from Carlsberg, Chr. Hansen and Novozymes.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.